Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05352828
Title Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION)
Acronym ACTION
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tessa Therapeutics
Indications
Therapies
Age Groups: senior | adult | child
Covered Countries USA


No variant requirements are available.